Description: Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease
Home Page: www.vervetx.com
VERV Technical Analysis
500 Technology Square
Cambridge,
MA
02139
United States
Phone:
617 603 0070
Officers
| Name | Title |
|---|---|
| Dr. Sekar Kathiresan M.D. | Co-Founder, CEO & Director |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Ms. Allison Dorval | CFO & Principal Accounting Officer |
| Dr. Andrew Bellinger M.D., Ph.D. | Chief Scientific Officer & Chief Medical Officer |
| Mr. Andrew D. Ashe J.D. | Pres & COO |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder & Sr. Scientific Advisor |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder |
| Mr. Issi Rozen M.B.A. | Co-Founder & Strategic Advisor |
| Ms. Margaret Beaudoin | VP of Fin. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 2.4982 |
| Price-to-Book MRQ: | 2.542 |
| Price-to-Sales TTM: | 1294.4093 |
| IPO Date: | 2021-06-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 113 |